Kyung Nam Pharm Decides Third-Party Allotment, 25.5% Share Dilution Raises Concerns for Existing Shareholders

Kyung Nam Pharm decided on a third-party allotment paid-in capital increase on June 23, 2026, raising 6.5 billion KRW in operating funds by issuing new shares to X Corp.
The new shares are priced at 1,629 KRW, a 10% discount from the reference price of 1,809 KRW. The issuance of 3,990,178 new shares represents a 25.5% dilution of existing shares outstanding of 15,629,471.
Payment date is July 1, 2026, and the new shares are expected to be listed on July 16, 2026. The allotted shares are subject to a one-year lock-up period.
[AI Summary]This capital increase by Kyung Nam Pharm causes a massive 25.5% dilution, negatively impacting existing shareholder value. While the funds are intended for operating activities, the near-term profitability outlook is uncertain, and the opaque financials of the third-party allottee increase investment risk.